Healthcare Sep 03, 2021 09:45 AM (GMT+8) · EqualOcean
The latest announcement by the State Food and Drug Administration of China: the car-t product of YaoMing junuo targeting CD19, Ricky orenza injection (trade name: benoda), has been officially approved for the treatment of recurrent or refractory large B-cell lymphoma in adult patients after second-line or above systematic treatment. This is the first innovative product of YaoMing junuo approved for listing, the second approved car-t product in China and the first car-t product of class 1 biological products.

This text is a result of machine translation.